We will review the use of pharmacogenomic tests in six therapeutic areas:
Cardiovascular and metabolic diseases
Infectious Diseases and Vaccines
Within each therapeutic area, we will include the following:
The gene or allele of interest
The functional effect of the gene or allele
The prevalence of the relevant alleles in various populations
The available genomic tests
A summary of the most significant clinical data available to date, regarding
Drug dosing and selection
And, finally recommendations for genomic testing from reputable peers, agencies and national guidelines.
Click links to view the video:
DNA methylation is a process by which methyl groups are added to DNA. Methylation modifies the function of the DNA, typically acting to suppress gene transcription. DNA methylation is essential for normal development and is associated with a number of key processes including genomic imprinting, X-chromosome inactivation, suppression of repetitive elements, and carcinogenesis.
Mary V. Relling, Pharm.D. joined St. Jude as a faculty member in 1988, and in 2003 was named chair of the Department of Pharmaceutical Sciences. She is also a professor at The University of Tennessee in the colleges of Medicine and Pharmacy. Her primary interests are in the treatment of childhood leukemia and pharmacogenetics of anti-leukemic therapy. Dr. Relling is one of the principal investigators within the National Institutes of Health Pharmacogenomics Research Network and co-founder of the Clinical Pharmacogenetics Implementation Consortium.
Applied pharmacogenomics resolves patient’s lifelong anxiety and depression.